GlassScriptPhysician profile
Nathan Goldsmith
NPI 1962072967
$1,509.18
in general payments reported to CMS, 2019-2025
16 companies · $1,305 in 2025
The $1,305 reported for 2025 was more than what 85% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $103 · 2022: $101 · 2025: $1,305.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,305.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,304.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $175.72 | 2022-2025 | Caplyta |
| Abbvie INC. | $168.23 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $166.45 | 2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $164.21 | 2025 | Spravato |
| Axsome Therapeutics, INC. | $151.80 | 2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $109.93 | 2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $104.52 | 2025 | |
| Corium, LLC | $97.27 | 2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $80.27 | 2025 | Trintellix |
| Lundbeck LLC | $76.03 | 2025 | Rexulti |
| Almatica Pharma LLC | $56.17 | 2025 | Loreev Xr |
| Alkermes, INC. | $52.33 | 2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $32.65 | 2025 | Austedo Xr |
| Neos Therapeutics, LP | $30.17 | 2025 | Adzenys Xr-Odt |
| Bausch Health US, LLC | $24.79 | 2025 | Aplenzin |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $18.64 | 2025 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Goldsmith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.